 |
PDBsum entry 1k2p
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.2
- non-specific protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
276:41435-41443
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.
|
|
C.Mao,
M.Zhou,
F.M.Uckun.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Bruton's tyrosine kinase is intimately involved in signal transduction pathways
regulating survival, activation, proliferation, and differentiation of B lineage
lymphoid cells. Mutations in the human btk gene are the cause of X-linked
agammaglobulinemia, a male immune deficiency disorder characterized by a lack of
mature, immunoglobulin-producing B lymphocytes. We have determined the x-ray
crystal structure of the Bruton's tyrosine kinase kinase domain in its
unphosphorylated state to a 2.1 A resolution. A comparison with the structures
of other tyrosine kinases and a possible mechanism of activation unique to
Bruton's tyrosine kinase are provided.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Fig. 2. Panel a, backbone positions of the A loop and
C helix for
BTK-KD (green), phospho-LCK (red), and c-SRC (white) are
superimposed to illustrate their conformational differences and
similarities. An AMP-PNP molecule ( pink) is present in the
c-SRC crystal structure and was used to mark the location of
active site. The side chains of Arg-544 and Tyr-551 in BTK and
their equivalent residues in LCK and c-SRC on the A loop are
shown. All coordinates were superimposed in CHAIN (28). Prepared
using Insight II. Panel b, the noninhibitory (BTK) and
inhibitory (IRK) conformations of the A loop are illustrated.
Both crystal structures were first superimposed and shown
separately in the same orientation with the A loops highlighted
in rainbow tubes. Neither of the activation tyrosines is
phosphorylated in the crystal structures. Prepared with GRASP
(56).
|
 |
Figure 3.
Fig. 3. Unique activation mechanism proposed based on the
crystal structures of BTK-KD and phospho-LCK. Panel A,
comparison of the superimposed BTK-KD (white backbones and
multiple color side chains in stick model) and the phospho-LCK
structures (gold backbones and red stick model side chains). The
black lines indicate hydrogen bonds. Panel B, we propose that
critical changes may occur when Arg-544 solely interacts with
phosphotyrosine 551 upon phosphorylation and Arg-544 releases
Glu-445, which subsequently takes part in ATP binding, which may
be a critical component of catalysis. N-lobe, N-terminal lobe;
C-lobe, C-terminal lobe.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2001,
276,
41435-41443)
copyright 2001.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Kuglstatter,
A.Wong,
S.Tsing,
S.W.Lee,
Y.Lou,
A.G.Villaseñor,
J.M.Bradshaw,
D.Shaw,
J.W.Barnett,
and
M.F.Browner
(2011).
Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.
|
| |
Protein Sci,
20,
428-436.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.J.Marcotte,
Y.T.Liu,
R.M.Arduini,
C.A.Hession,
K.Miatkowski,
C.P.Wildes,
P.F.Cullen,
V.Hong,
B.T.Hopkins,
E.Mertsching,
T.J.Jenkins,
M.J.Romanowski,
D.P.Baker,
and
L.F.Silvian
(2010).
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.
|
| |
Protein Sci,
19,
429-439.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Sacristán,
S.A.Schattgen,
L.J.Berg,
S.C.Bunnell,
A.L.Roy,
and
Y.Rosenstein
(2009).
Characterization of a novel interaction between transcription factor TFII-I and the inducible tyrosine kinase in T cells.
|
| |
Eur J Immunol,
39,
2584-2595.
|
 |
|
|
|
|
 |
R.E.Joseph,
and
A.H.Andreotti
(2009).
Conformational snapshots of Tec kinases during signaling.
|
| |
Immunol Rev,
228,
74-92.
|
 |
|
|
|
|
 |
F.M.Uckun
(2008).
Clinical potential of targeting Bruton's tyrosine kinase.
|
| |
Int Rev Immunol,
27,
43-69.
|
 |
|
|
|
|
 |
O.Hantschel,
U.Rix,
U.Schmidt,
T.Bürckstümmer,
M.Kneidinger,
G.Schütze,
J.Colinge,
K.L.Bennett,
W.Ellmeier,
P.Valent,
and
G.Superti-Furga
(2007).
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
|
| |
Proc Natl Acad Sci U S A,
104,
13283-13288.
|
 |
|
|
|
|
 |
Z.Pan,
H.Scheerens,
S.J.Li,
B.E.Schultz,
P.A.Sprengeler,
L.C.Burrill,
R.V.Mendonca,
M.D.Sweeney,
K.C.Scott,
P.G.Grothaus,
D.A.Jeffery,
J.M.Spoerke,
L.A.Honigberg,
P.R.Young,
S.A.Dalrymple,
and
J.T.Palmer
(2007).
Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase.
|
| |
ChemMedChem,
2,
58-61.
|
 |
|
|
|
|
 |
J.Väliaho,
C.I.Smith,
and
M.Vihinen
(2006).
BTKbase: the mutation database for X-linked agammaglobulinemia.
|
| |
Hum Mutat,
27,
1209-1217.
|
 |
|
|
|
|
 |
J.M.Lindvall,
K.E.Blomberg,
J.Väliaho,
L.Vargas,
J.E.Heinonen,
A.Berglöf,
A.J.Mohamed,
B.F.Nore,
M.Vihinen,
and
C.I.Smith
(2005).
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
|
| |
Immunol Rev,
203,
200-215.
|
 |
|
|
|
|
 |
L.J.Berg,
L.D.Finkelstein,
J.A.Lucas,
and
P.L.Schwartzberg
(2005).
Tec family kinases in T lymphocyte development and function.
|
| |
Annu Rev Immunol,
23,
549-600.
|
 |
|
|
|
|
 |
R.L.Levine,
M.Wadleigh,
J.Cools,
B.L.Ebert,
G.Wernig,
B.J.Huntly,
T.J.Boggon,
I.Wlodarska,
J.J.Clark,
S.Moore,
J.Adelsperger,
S.Koo,
J.C.Lee,
S.Gabriel,
T.Mercher,
A.D'Andrea,
S.Fröhling,
K.Döhner,
P.Marynen,
P.Vandenberghe,
R.A.Mesa,
A.Tefferi,
J.D.Griffin,
M.J.Eck,
W.R.Sellers,
M.Meyerson,
T.R.Golub,
S.J.Lee,
and
D.G.Gilliland
(2005).
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
|
| |
Cancer Cell,
7,
387-397.
|
 |
|
|
|
|
 |
C.Luo,
and
P.Laaja
(2004).
Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs.
|
| |
Drug Discov Today,
9,
268-275.
|
 |
|
|
|
|
 |
S.Guo,
G.Z.Ferl,
R.Deora,
M.Riedinger,
S.Yin,
J.L.Kerwin,
J.A.Loo,
and
O.N.Witte
(2004).
A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.
|
| |
Proc Natl Acad Sci U S A,
101,
14180-14185.
|
 |
|
|
|
|
 |
J.A.Márquez,
C.I.Smith,
M.V.Petoukhov,
P.Lo Surdo,
P.T.Mattsson,
M.Knekt,
A.Westlund,
K.Scheffzek,
M.Saraste,
and
D.I.Svergun
(2003).
Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering.
|
| |
EMBO J,
22,
4616-4624.
|
 |
|
|
|
|
 |
P.A.Goodman,
C.M.Wood,
A.O.Vassilev,
C.Mao,
and
F.M.Uckun
(2003).
Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.
|
| |
Leuk Lymphoma,
44,
1011-1018.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |